Novartis Hits Par With Second Lotrel Suit

Law360, New York (January 4, 2007, 12:00 AM EST) -- Swiss pharmaceutical giant Novartis International AG has filed another patent suit against Par Pharmaceuticals, seeking to protect the market for billion-dollar hypertension treatment Lotrel.

The latest lawsuit, filed on December 29 in New Jersey, names Par Pharmaceutical Companies Inc. and two Par subsidiaries as defendants. It follows another patent infringement suit over Lotrel filed by the same plaintiffs against the same defendants in the same court on October 4, 2006.

The complaints are virtually identical, although the more recent complaint references an amendment to Par’s Abbreviated...
To view the full article, register now.